论文部分内容阅读
目的 :探讨异基因外周血造血干细胞移植治疗恶性血液病的疗效。方法 :用异基因外周血造血干细胞移植治疗恶性血液病 4例 ,预处理方案用TBI 8- 9Gy(分 2d) +CTX 12 0mg/kg。预防移植物抗缩主病 (GVHD)用CSA +短程MTX。结果 :全部患者移植后重建造血 ,DNA序列分析表明 1个月内移植物植入 ,4例患者均出现不同程度的GVHD ,1例出现Ⅳ度aGVHD ,移植后 2个月死于颅内出血 ,其余 3例仍完全缓解 (CR) ,最长者达 16个月。结论 :ALLO -PBSCT是目前治疗恶性血液病最有效的方法之一 ,防治GVHD仍然是临床移植中的一个重要问题。
Objective: To investigate the efficacy of allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies. Methods: Allogeneic peripheral blood stem cell transplantation for the treatment of 4 cases of hematological malignancies, pretreatment program with TBI 8- 9Gy (2d) + CTX 120mg / kg. Prevention of graft-versus-host disease (GVHD) with CSA + short-term MTX. Results: All the patients had hematopoietic reconstitution after transplantation. The DNA sequence analysis showed that the grafts were implanted within 1 month. All 4 patients had varying degrees of GVHD, 1 case had grade Ⅳ aGVHD, 2 months after transplantation died of intracranial hemorrhage, and the rest 3 patients were still completely relieved (CR), the longest up to 16 months. Conclusion: ALLO-PBSC is one of the most effective methods for the treatment of hematologic malignancies. Prevention and treatment of GVHD is still an important issue in clinical transplantation.